Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Total Current Liabilities (2018 - 2025)

Inmune Bio's Total Current Liabilities history spans 8 years, with the latest figure at $7.4 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 46.78% year-over-year to $7.4 million; the TTM value through Sep 2025 reached $7.4 million, down 46.78%, while the annual FY2024 figure was $7.2 million, 60.89% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $7.4 million at Inmune Bio, down from $8.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $18.5 million in Q4 2023 and bottomed at $2.2 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $7.9 million (2025), against an average of $9.0 million.
  • The largest annual shift saw Total Current Liabilities soared 471.33% in 2023 before it tumbled 60.89% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $4.4 million in 2021, then surged by 150.47% to $10.9 million in 2022, then skyrocketed by 69.12% to $18.5 million in 2023, then crashed by 60.89% to $7.2 million in 2024, then rose by 1.88% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Total Current Liabilities are $7.4 million (Q3 2025), $8.6 million (Q2 2025), and $7.9 million (Q1 2025).